SCHEMBL7465101

SCHEMBL7465101

NC(=O)OC(=O)NCC(OC(N)=O)c1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 5/20 0.44
AVPR1A P37288 5/20 0.44
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ADRB2 P07550 2/20 0.35
ADRB1 P08588 2/20 0.35
OPRM1 P35372 2/20 0.35
ATM Q13315 1/20 0.35
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35
HIF1A Q16665 1/20 0.35
BLM P54132 1/20 0.34
CXCL8 P10145 1/20 0.34
CASP1 P29466 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7467171 1.00 AVPR2 (0.44) AVPR2AVPR1ALMNAMAPTADRB2
SCHEMBL7476504 1.00 AVPR2 (0.44) AVPR2AVPR1ALMNAMAPTADRB2
SCHEMBL8198317 0.90 AVPR2 (0.38) AVPR2AVPR1ALMNAMAPTADRB2
SCHEMBL7804157 0.88 ADRB2 (0.39) AVPR2AVPR1ALMNAMAPTADRB2
SCHEMBL7796205 0.86 KMT2A (0.43) AVPR2AVPR1AOPRM1
SCHEMBL7464065 0.85 RAB9A (0.34) AVPR2AVPR1ALMNAMAPTCYP2D6
SCHEMBL4602555 0.85 RAB9A (0.34) AVPR2AVPR1ALMNAMAPTCYP2D6
SCHEMBL7465481 0.83 ADRB1 (0.50) LMNAMAPTADRB2ADRB1OPRM1
SCHEMBL2904416 0.83 ADRB1 (0.50) LMNAMAPTADRB2ADRB1OPRM1
SCHEMBL7470205 0.83 ADRB1 (0.50) LMNAMAPTADRB2ADRB1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6127412-A TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANTICONVULSANTS, ANTIEPILEPTIC AND NEUROPROTECTIVE AGENTS AND CENTRALLY ACTING MUSCLE RELAXANTS SK CORPORATION (US) 2000-10-03 US claimed
EP-0907635-B1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK CORP (KR) 2002-09-25 EP disclosed
US-20010034365-A1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol CHOI YONG MOON (US) 2001-10-25 US disclosed
US-6127412-A TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANTICONVULSANTS, ANTIEPILEPTIC AND NEUROPROTECTIVE AGENTS AND CENTRALLY ACTING MUSCLE RELAXANTS SK CORPORATION (US) 2000-10-03 US disclosed
US-6103759-A COMPRISING PURE ENANTIOMERIC FORMS, AS WELL AS ENANTIOMERIC MIXTURES, OF (2-(2-CHLOROPHENYL)-2-HYDROXYETHYL)OXYCARBOXAMIDE; USEFUL FOR TRATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SK CORPORATION (US) 2000-08-15 US disclosed
EP-0907635-A1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK Corporation (KR) 1999-04-14 EP disclosed
US-5854283-A Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol YUKONG LIMITED (KR) 1998-12-29 US disclosed
WO-1997026241-A1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK CORPORATION (KR) 1997-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034365-A1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol DDT, GRIK2, GABRD AVPR2 375/4885AVPR1A 933/4885LMNA 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.